Thus, the existing CAR T cells are mostly targeting CD19, which is a specific antigen for B‐cells, with impressive results in B‐cell acute lymphoblastic leukaemia and B‐cell non‐Hodgkin lymphomas.22 The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.